Metraipolis › archive › dc_3801fd390ff9

Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics… — Europe PMC PMID:42383207

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42383207
DOI
10.1016/j.conctc.2026.101660
License (as archived)
solo-consultazione
Archived
2026-10-19T08:00:11.324Z
SHA-256 of the archived text
387208c12b10ca38762d047e4e12437ff8c1518232c697d40a4c6367c56f4e4b
Stable URL of this page
https://metraipolis.com/documento/dc_3801fd390ff9

How to cite

Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics… — Europe PMC PMID:42383207 — Europe PMC (en), https://europepmc.org/article/MED/42383207 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3801fd390ff9 (Metraipolis archive dc_3801fd390ff9, sha256 387208c12b10ca38762d047e4e12437ff8c1518232c697d40a4c6367c56f4e4b)
BibTeX
@misc{dc3801fd390ff9,
  title = {Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics… — Europe PMC PMID:42383207},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42383207},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3801fd390ff9; sha256 387208c12b10ca38762d047e4e12437ff8c1518232c697d40a4c6367c56f4e4b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42383207. Agents can read the archived copy with the MCP tool read_document.